Liraglutide and Exercise: The Real Impact on Body Composition for Sustainable Weight Loss
We compile, generate and translate using Artificial Intelligence from the below given source. Macro Micro News is responsible for its editorial publication.
Belgrade, Serbia, Source:
Obesity is increasingly recognized as a chronic, relapsing disease with significant cardiometabolic risks, necessitating treatment strategies that go beyond simple weight reduction. Recent real-world data from a prospective cohort study conducted in Belgrade highlights the nuanced impact of liraglutide 3.0 mg therapy combined with medical nutrition therapy (MNT) and structured exercise on body composition and quality of life. The study, involving 70 adults with overweight or obesity, sought to determine whether participation in a supervised exercise program influences the quality of weight loss, specifically regarding the preservation of fat-free mass (FFM) and skeletal muscle mass (SMM).
Participants were divided into a Structured Exercise Group (SEG, n=23) and a Non-Structured Exercise Group (NSEG, n=47). Both groups received standardized MNT with targeted protein intake; however, the SEG was prescribed higher protein targets (1.4–2.0 g/kg/day) compared to the NSEG (1.2 g/kg/day), aligning with international sports nutrition guidelines for active individuals. Over a 12-month period, sex-adjusted models revealed significant reductions in body weight, BMI, waist circumference, and fat mass (FM) across both groups. Notably, there were no significant differences in the absolute trajectories of body weight, FM, FFM, or SMM between the two groups, indicating that liraglutide effectively drives weight loss regardless of exercise participation.
However, exploratory analyses uncovered critical differences in the composition of that weight loss. For every kilogram of total body weight lost, participants in the SEG experienced a significantly greater reduction in fat mass (0.78 kg vs. 0.45 kg in NSEG) and a smaller loss of fat-free mass and skeletal muscle mass. This suggests that while the total amount of weight lost may be similar, the SEG achieved a more favorable body composition profile, preserving metabolically active tissue while shedding adipose tissue. This finding is clinically vital, as preserving muscle mass helps maintain basal metabolic rates and supports long-term weight maintenance.
Metabolic parameters also improved significantly, including reductions in glucose, HbA1c, total cholesterol, LDL-C, and triglycerides, though HDL-C levels did not change significantly. Quality of life assessments using the EQ-5D-5L questionnaire showed marked improvements in mobility, pain/discomfort, and anxiety/depression domains at six months for both groups, with no statistically significant difference between them.
The study underscores that while pharmacological interventions like liraglutide are highly effective for weight reduction, combining them with structured physical activity and optimized nutritional support may enhance the quality of weight loss by prioritizing fat loss over muscle loss. Although the non-randomized design and differing protein prescriptions limit definitive causal conclusions, the results provide compelling evidence for multimodal approaches in obesity management. Future research should focus on larger, randomized trials to isolate the specific contributions of exercise intensity, volume, and dietary adherence to these beneficial compositional changes.